"I think that what most people will find is, if you're in an academic center, it can be a little bit difficult to set up a nitrous oxide program because there is a lot of red tape for bringing a gas into the ambulatory setting," says Heidi J. Rayala, MD, PhD.
“So, my take home message for the urology community is even if you're not doing clinical trials, we already have FDA-approved, CMS-covered, most commercial insurances-covered genetic alterations now for our CRPC populations, and there will be more to come,” says Neal D. Shore, MD, FACS.
“I think we should all be pretty selective in whom we're operating on in the metastasectomy setting,” says Harras B. Zaid, MD.
Neal Shore, MD, FACS, reviews agents and treatment options being researched in the BCG-unresponsive NMIBC treatment space.
Following a review of rectal spacer options, Varun Sundaram, MD, offers clinical perspectives on hyaluronic acid spacers for patients with prostate cancer undergoing radiation.
Following a review of the limitations of current treatment options, Neal Shore, MD, MFACS, discusses the SunRISe-1 trial investigating TAR-200 plus cetrelimab in patients with high-risk NMIBC.
Clinical insights on challenges and complications of rectal spacing encountered in the treatment of patients with prostate cancer.
Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.
The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.
With multiple PSMA PET tracers available, Jaideep S. Sohi, MD, shares insights about the benefits of the various options and his real-world experience with their use in practice.
A prostate imaging expert shares tips for how to interpret PSMA PET/CT imaging results as well as when re-imaging is recommended.
Jaideep S. Sohi, MD, discusses how PSMA PET imaging has impacted diagnosis and management of prostate cancer in clinical practice, when and why it should be considered over conventional imaging, and which PSMA PET tracers are available.
“As far as that point of max curve, I would say this is pretty definitive that this is something that needs to be done and changed within someone's practice,” says Landon Trost, MD.
Experts discuss grading, staging, and risk stratification of Non-Muscle Invasive Bladder Cancer (NMIBC). Panelists highlight differentiation between the risks of recurrence and progression, emphasizing the importance of categorizing patients into low, intermediate, and high-risk groups based on various factors, including tumor size, grade, and history of recurrence. The importance of continuous prospective observation of patients with NMIBC is emphasized.
"The study was done between April 2021 to 2023, so a 2-year span. It was surprising to find that 24% of our patients in that time span had opioid-free discharge," says Katherine Wang, MD.
Experts in urology discuss the importance of evaluation to accurately identify the stage and grade of NMIBC, which plays a crucial role in determining the risk category focusing on the distinction between low and high-grade tumors and the significance for each patient with NMIBC.
Christopher M. Pieczonka, MD and Jose De La Cerda, MD, MPH share their expertise in managing metastatic castration-resistant prostate cancer (mCRPC), focusing on the demographics in their distinct clinical practices and unique challenges they encounter nuances of treatment.
In this Urology Times® episode, Dr. Kennelly, Dr. Kevin Benson, and Dr. Karyn Eilber discuss overactive bladder (OAB), focusing on its diagnosis, symptomatology, and patient populations most at risk, including gender and age-related factors.
Bogdana Schmidt, MD, MPH, outlines key bladder cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.
“When it comes to this, I think having a great team around you is really so important,” says Bree Duncan, RN, BSN.
"Again, operating has more and more taken a backseat as the armamentarium of systemic medications, especially checkpoint inhibitors [and] combination treatments, has exploded," says Harras B. Zaid, MD.
“I love helping people to connect with their passions and to find and create the lives that they wish to create, both within the field of medicine and urology,” says Anne M. Suskind, MD, MS, FACS, FPMRS.
Janet Kukreja, MD, outlines key kidney cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.
“I think if you were to ask what surprised me, I didn't expect it to have more of an effect on pain than anxiety,” says Heidi J. Rayala, MD, PhD.
“What it brought up is the point that where the field seems to be going is incorporating the PET imaging and the MRI imaging, and maybe PET MRI,” says Michael S. Cookson, MD, MMHC, FACS.
Specialists in the field of prostate cancer discuss their approaches for discussing rectal spacing with patients.
Comprehensive insights on the utilization of rectal spacers with proton beam radiation and brachytherapy in prostate cancer.
“It's exhausting and it's overwhelming, but traction has been gained and continues to be gained and we are making some meaningful, tangible differences,” says Mara R. Holton, MD.
Comprehensive insights on treatment considerations and managing immunotherapy-related adverse effects for patients with bladder cancer.
The panel discusses strategies for monitoring patients with non–muscle invasive bladder cancer and the potential role of biomarkers.
